UK patients save over £1 billion in prescription costs through PPCs

26 March 2025

The NHS Business Services Authority (NHSBSA) has released an exploratory analysis estimating that patients could have faced prescription charges totaling approximately £837 million ($1.1 billion) in the 2023/24 period without the use of prescription prepayment certificates.

The report indicates that over three million PPCs were issued during this timeframe, with more than two-thirds being 12-month certificates - a figure that has seen consistent growth since 2018/19. Additionally, almost a million three-month certificates were distributed, marking an overall increase over the past five years.

Experimental analysis of NHS prescriptions data suggests that, without a three or 12-month PPC, patients might have incurred approximately £817 million in prescription charges. The NHSBSA plans to publish this report annually to provide ongoing insights into PPC uptake and potential patient savings.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical